title: Ipilimumab-associated bilateral optic neuropathy.
abstract: Ipilimumab is a novel monoclonal antibody targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) receptor that has been shown to improve survival in metastatic melanoma. Previous case reports have documented its association with drug-induced uveitis. We report a patient who developed bilateral optic neuropathy with disc edema while taking this medication.
authors: Department of Ophthalmology, University of Washington, Seattle, Washington.
authors: Oliver L
authors: OL
authors: Yeh
authors: Courtney E
authors: CE
authors: Francis
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D009901:Optic Nerve Diseases / Q000139:chemically induced* / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D000074324:Ipilimumab